Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan

A local epidemiological survey of psoriasis was conducted from 19 February to 30 June 2016 in Matsumoto city, Nagano Prefecture, Japan. Patients were predominantly male (268 cases, 71.5% males vs 107 cases, 28.5% females). We estimated that the prevalence of psoriasis was 0.097% in the Matsumoto are...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2018-03, Vol.45 (3), p.314-317
Main Authors: Ogawa, Eisaku, Okuyama, Ryuhei, Seki, Tomoko, Kobayashi, Aya, Oiso, Naoki, Muto, Masahiko, Nakagawa, Hidemi, Kawada, Akira
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Arthritis
Biological Products - therapeutic use
Child
Child, Preschool
Corticosteroids
Epidemiology
examination
Female
Health Surveys - statistics & numerical data
Humans
Infliximab
Japan
Male
Methotrexate
Middle Aged
Monoclonal antibodies
Phototherapy
Prevalence
Psoralen
Psoriasis
Psoriasis - epidemiology
Psoriasis - therapy
Psoriasis vulgaris
Psoriatic arthritis
therapeutics
Tumor necrosis factor-α
Ultraviolet radiation
Ultraviolet Therapy - methods
Ultraviolet Therapy - statistics & numerical data
Vitamin D3
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A local epidemiological survey of psoriasis was conducted from 19 February to 30 June 2016 in Matsumoto city, Nagano Prefecture, Japan. Patients were predominantly male (268 cases, 71.5% males vs 107 cases, 28.5% females). We estimated that the prevalence of psoriasis was 0.097% in the Matsumoto area. The clinical types of psoriasis identified were psoriasis vulgaris (90.7%), psoriatic arthritis (5.9%), pustular psoriasis (2.1%), guttate psoriasis (1.0%) and psoriatic erythroderma (0.3%). The topical therapeutic agents included corticosteroids (84.0%), vitamin D3 analogs (61.5%), and a combination of calcipotriol and betamethasone dipropionate (31.0%). Current systemic treatments included cyclosporin (9.0%), etretinate (7.4%) and methotrexate (1.3%). Biologic treatments included adalimumab (4.0%), ustekinumab (2.7%), infliximab (1.3%) and secukinumab (0.8%). Ultraviolet B therapy (11.3%) was the predominant phototherapy in which narrow band ultraviolet B therapy accounted for the majority, followed by psoralen and ultraviolet A therapy (1.0%). According to the recent evolution of psoriasis treatment, the use of biologics has been increasing. This study demonstrates the changes of treatment trends of psoriasis in a non‐metropolitan regional area.
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.14101